CHS 131

Drug Profile

CHS 131

Alternative Names: AMG 131; INT 131; INT131 besylate; T 0903131; T 131

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tularik
  • Developer Coherus BioSciences; InteKrin Therapeutics
  • Class Anti-inflammatories; Antihypercalcaemics; Antihyperglycaemics; Insulin sensitisers; Neuroprotectants; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; Peroxisome proliferator-activated receptor gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Type 2 diabetes mellitus

Most Recent Events

  • 28 Apr 2017 Efficacy data from a phase IIb trial in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 13 Mar 2017 CHS 131 is available for licensing as of 13 Mar 2017. https://www.coherus.com/our-scientific-platform/
  • 31 Dec 2016 Coherus BioSciences completes a phase IIb trial in Multiple Sclerosis in Russia before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top